PRGO.TA - Perrigo Company plc

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
25,160.00
-410.00 (-1.60%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close25,570.00
Open25,400.00
Bid25,160.00 x 7100
Ask25,180.00 x 29700
Day's Range24,990.00 - 25,450.00
52 Week Range24,990.00 - 32,700.00
Volume110,099
Avg. Volume62,530
Market Cap32.825B
Beta0.80
PE Ratio (TTM)27,801.11
EPS (TTM)0.90
Earnings DateN/A
Forward Dividend & Yield2.77 (1.00%)
Ex-Dividend Date2018-05-31
1y Target Est86.00
  • Benzinga5 days ago

    Perrigo Needs 'Meet-Or-Beat' Quarters, Deutsche Bank Says In Downgrade

    Perrigo Company PLC, (NYSE: PRGO ) was hit with a downgrade from Deutsche Bank after an eventful week that included the announced separation of its prescription pharmaceutical business and its second-quarter ...

  • The Wall Street Journal6 days ago

    [$$] Perrigo to Separate Its Prescription Pharmaceutical Business

    Perrigo Co. plans to shed its prescription pharmaceutical unit, which accounts for about one-fifth of total revenue, following a strategic review of its portfolio. Perrigo, which makes private-label products such as cold medicines and infant formula, said Thursday its board believes the separation would create shareholder value and allow the company to focus on expanding its consumer business. Perrigo said it plans to complete the separation in the second half of 2019.

  • Barrons.com6 days ago

    Mylan, Perrigo Earnings: Look Out Below!

    Shares of Mylan (MYL) and Perrigo (PRGO) are falling on Thursday after the drugmakers revised their full-year outlooks lower. Where we were: While health-care and pharmaceutical stocks have outperformed the broader market, both Perrigo and Mylan have been left out of the party, falling 19.1% and 12.7%, respectively, year to date. The second-quarter earnings season has been quite strong, but it's been a tough couple of days for specialty pharmaceutical companies.

  • Generic Drugmakers Struggle Despite U.S. Push for Copycats
    Bloomberg6 days ago

    Generic Drugmakers Struggle Despite U.S. Push for Copycats

    Generic drugmakers are being crushed by the very forces that the Trump administration is counting on to drive down prescription costs. While policy makers are betting that opening the market to a deluge of new medicines and reforming the drug supply chain will help contain rising prices, many widely used copycat medications are already seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water. As a result, companies including Mylan NV and Perrigo Co. are being forced to consider shakeups.

  • Perrigo plans to separate prescription pharma business
    Reuters6 days ago

    Perrigo plans to separate prescription pharma business

    Generic drugmakers such as Perrigo, Mylan (MYL.O) and Teva Pharmaceutical Industries (TEVA.TA) have suffered over the past few years as price erosion has pressured their bottom lines. "The company (Perrigo) has been actively discussing this potential separation for some time and the lack of a buyer thus far to us suggests this won't be easy," RBC Capital Markets analyst Randall Stanicky said. Perrigo's announcement comes just a day after larger rival Mylan said it was evaluating all strategic options, citing a tough U.S. environment for generic drugmakers.

  • Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down
    Zacks6 days ago

    Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down

    Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.

  • CNBC6 days ago

    Stocks making the biggest moves premarket: VIAB, TRCO, BKNG, PRTY & more

    Check out the companies making headlines before the bell: Viacom VIAB – The media company reported adjusted quarterly profit of $1.18 per share , 11 cents a share above estimates. Revenue was essentially in line with forecasts, but was down about 3.

  • Perrigo (PRGO) Beats Q2 Earnings Estimates
    Zacks6 days ago

    Perrigo (PRGO) Beats Q2 Earnings Estimates

    Perrigo (PRGO) delivered earnings and revenue surprises of 0.83% and -3.48%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 days ago

    Perrigo: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to $1.22 per share. The results surpassed Wall Street expectations. ...

  • Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
    PR Newswire7 days ago

    Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

    TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter ("OTC") Nasonex® (mometasone furoate monohydrate) Nasal Spray. Under the terms of the agreement, Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex® OTC in the United States following Perrigo's receipt of all necessary regulatory approvals.

  • Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business
    PR Newswire7 days ago

    Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business

    TASE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's previously announced strategic portfolio review. Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical products and allows Perrigo to focus on expanding its leading consumer business. Chairman of the Board of Directors, Rolf Classon stated, "Perrigo's Board of Directors is committed to shareholder value creation.

  • Perrigo Company plc Reports Second Quarter 2018 Financial Results
    PR Newswire7 days ago

    Perrigo Company plc Reports Second Quarter 2018 Financial Results

    DUBLIN , Aug. 9, 2018 /PRNewswire/ -- Realized second quarter 2018 GAAP ("reported") net sales of $1.2 billion , reported net income of $36 million compared to a net loss of $70 million last ...

  • Benzinga7 days ago

    Perrigo's Q2 Earnings Preview

    Perrigo (NYSE: PRGO ) releases its next round of earnings Thursday. Here's Benzinga's essential guide to Perrigo's Q2 earnings report. Earnings and Revenue Based on Perrigo management projections, analysts ...

  • Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More
    Zacks7 days ago

    Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More

    Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zacks7 days ago

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.

  • Perrigo Announces Quarterly Dividend
    PR Newswire14 days ago

    Perrigo Announces Quarterly Dividend

    Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market.

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Perrigo To Release Second Quarter Calendar Year 2018 Financial Results On August 9, 2018
    PR Newswire20 days ago

    Perrigo To Release Second Quarter Calendar Year 2018 Financial Results On August 9, 2018

    TASE: PRGO) today announced that it will release its second quarter calendar year 2018 financial results on Thursday, August 9, 2018. The Company will host a conference call beginning at 8:30 a.m. (EDT). Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.

  • S&P 500’s Top Gainers: Perrigo and Charles Schwab
    Market Realist28 days ago

    S&P 500’s Top Gainers: Perrigo and Charles Schwab

    The S&P 500’s top gainers on July 17 were: Perrigo (PRGO) gained 3.98%. Charles Schwab (SCHW) gained 3.56%. Johnson & Johnson (JNJ) gained 3.54%. Lam Research (LRCX) gained 3.17%. Aptiv (APTV) gained 2.98%. Perrigo

  • Barrons.com29 days ago

    After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher

    Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.

  • Benzingalast month

    Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings

    The iShares Dow Jones US Healthcare (ETF) (NYSE: IYH ) is up marginally year-to-date, but the profits aren’t bleeding into all health care constituents. The Ratings Goldman Sachs analyst Jami Rubin upgraded ...

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Should You Buy Perrigo Company plc (NYSE:PRGO) Based On These Aspects?
    Simply Wall St.2 months ago

    Should You Buy Perrigo Company plc (NYSE:PRGO) Based On These Aspects?

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...